Introduction {#Sec1}
============

There is a worldwide steady and growing use of permanent pacemakers (PPMs); every year 600,000 PPMs are implanted and this number is increasing \[[@CR1]\]. Interestingly, 50--75% of patients with a PPM may have an indication for MRI scanning during their lifetime, which urged the development of MRI-compatible PPM \[[@CR2]\]. In 2011, the US Food and Drug Administration approved the first MRI-conditional pacing system in the United States: the Medtronic Revo SureScan Pacing System, the Generator and two CapSureFix MRI 5086 active-fixation pacing leads. To minimise the effects of the magnetic field, multiple design changes have been incorporated, which led to a stiffer lead that transfers more torque than other modern active fixation leads \[[@CR3]\]. Many trials have confirmed the safety of performing MRI scanning on patients with these devices but very few looked at the safety of implantations and outcomes of the actual procedures \[[@CR4], [@CR5]\]. We thus conducted a meta-analysis to examine specifically the safety of MRI-conditional pacing systems in comparison with conventional systems.

Methods {#Sec2}
=======

Literature search and data sources {#Sec3}
----------------------------------

An electronic literature search was performed by two investigators (MS, AK) using PubMed until 28 August 2017. The search terms were: pacemaker AND magnetic resonance imaging. Neither language nor demographic restrictions were applied. All references from papers obtained through the database were reviewed manually. In addition, we performed a manual web search looking at different manufacturers' databases as well as conference websites and proceedings. We only included full papers and excluded reports that did not provide full data about the outcomes of interest. The electronic search has been archived and is available upon request.

Study selection and quality assessment {#Sec4}
--------------------------------------

The inclusion was limited to studies which:compared the outcomes of interest between patients receiving MRI-conditional PPMs (MRI group) versus conventional PPMs (control group);included an adult population \>18 years old; andprovided comprehensive data on outcomes of interest.

The selection of studies was assessed independently by three assessors (MS, AK, TS). We excluded non-comparative trials, crossover studies, case reports, editorials, letters, replies, and reviews.

Data extraction {#Sec5}
---------------

Three reviewers (MS, AK, TS) independently extracted the data from published sources; disagreements were resolved by discussion and, when necessary, in consultation with other co-authors.

Outcomes of interest were:The rate of pacemaker lead dislodgement (atrial and ventricular);pericardial complications (including pericarditis, pericardial effusion and cardiac tamponade);overall complications; andpacemaker parameters including sensing and pacing thresholds and impedance.

Whenever possible, direct communication with the authors of the papers was undertaken in an attempt to obtain the data of interest if presentation in the manuscript was incomplete.

We used the Newcastle-Ottawa Scale to further assess the quality of the observational studies. Studies were judged on three broad perspectives:selection of the study groups;comparability of the groups; andascertainment of either the exposure or outcomes of interest for case-control or cohort studies, respectively \[[@CR6]\].

Statistics {#Sec6}
----------

The software package RevMan (version 5), provided by the Cochrane Collaboration, was used for combining outcomes from the individual studies and statistical analysis. Outcomes were pooled using a random-effects model described by DerSimonian and Laird \[[@CR7]\]. Summary estimates and 95% confidence intervals (CIs) were reported for dichotomous variables as odds ratio (OR). The heterogeneity between studies was assessed using Cochrane's *X*^*2*^ and *I*^*2*^. An *I*^*2*^ \> 50% was considered to represent significant heterogeneity \[[@CR8]\]. Statistical significance was set at *p* \< 0.05. We calculated the weighted means for the variable baseline characteristics and complication outcomes whenever possible. Otherwise we captured the medians with range or interquartile range as reported in the individual studies.

Results {#Sec7}
=======

Summary of the studies {#Sec8}
----------------------

The literature search resulted in 1,204 studies (1,129 from electronic databases and 75 from other resources including web searches and reference lists). We identified six studies (5 retrospective and 1 prospective non-randomised) that met all the inclusion criteria of this meta-analysis \[[@CR3], [@CR9]--[@CR13]\]. The information relevant to the literature search is shown in Fig. [1](#Fig1){ref-type="fig"}. All studies that met our inclusion criteria used the Medtronic Revo SureScan Pacing System (with Medtronic CapSureFix 5086 leads) as the MRI-conditional pacing system. Different pacing systems were used in the control group. Tab. [1](#Tab1){ref-type="table"} presents a summary of the included studies, the pacing systems used, and the follow-up periods in the individual studies.Fig. 1Flow diagram of literature search and study selectionTable 1Summary of included studiesStudy/YearType of StudyNo. of patientsType of LeadFollow-up(*n* = 5)MRI (*n* = 969)Control (*n* = 1,149)MRIControl(Months)Forleo 2010 \[[@CR10]\]Prospective, non-randomised, controlled study 50 57Medtronic CapSureFix 5086 MRI SureScanMedtronic CapSureFix Novus 407612Wollmann 2011 \[[@CR12]\]Retrospective study 39 59Medtronic CapSureFix 5086 MRI SureScanMedtronic 4592 (atrial leads); 4092 (ventricular leads) 6.5 ± 2.75^a^Elmouchi 2014 \[[@CR3]\]Retrospective case-control study 65 92Medtronic CapSureFix 5086 MRI SureScanMedtronic CapSureFix Novus 507614Rickard 2014 \[[@CR11]\]Retrospective cohort study466316Medtronic CapSureFix 5086 MRI SureScanMedtronic 5076 and Medtronic 4193 (left ventricular leads)25.5^b^44.3^c^Acha 2015 \[[@CR9]\]Retrospective, non-randomised, case-series study 72420Medtronic CapSureFix 5086 MRI SureScanCapSureFix Novus 4076 and 507634Kwon 2016 \[[@CR13]\]Retrospective study277205Medtronic CapSureFix 5086 MRI SureScanMedtronic CapSureFix Novus 5076 1^a^Mean ± standard deviation^b^Control group^c^MRI group

Baseline characteristics of patients {#Sec9}
------------------------------------

In total, 2,118 patients were included in this study. Medtronic MRI-conditional Revo SureScan Pacing Systems with 5086 leads (MRI group) were used in 969 patients. Baseline demographics and clinical characteristics were similar between the MRI and control group (age: 68 ± 2.4 vs. 72 ± 4.9 years, *p* = 0.11; male gender: 58% vs. 55%, *p* = 0.64; history of atrial arrhythmias: 39% vs. 29%, *p* = 0.43; hypertension: 55% vs. 62%, *p* = 0.97; and left ventricular ejection fraction: 60 ± 1.99 vs. 60 ± 3.70, *p* = 0.60). A summary of the baseline characteristics is presented in Tab. [2](#Tab2){ref-type="table"}.Table 2Patient baseline characteristicsVariableMRIControl*P*-valueTotal patients (no.)9691,149*n*/aAge (years) (mean ± SD) 68 ± 2.43  72 ± 4.890.109Male gender 58%  55%0.635History of atrial arrhythmias 39%  29%0.432Hypertension 55%  62%0.967Left ventricular ejection fraction 60 ± 1.99%  60 ± 3.70%0.603*n/a* not applicable

Outcomes of interest {#Sec10}
--------------------

The rate of pacemaker lead dislodgement (atrial and ventricular) was significantly higher in the MRI group (3% vs. 1%, OR 2.47 (95% CI 1.26; 4.83), *p* = 0.008). No significant heterogeneity was noted for this comparison (*I*^*2*^ = 0%, *p* = 0.62) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forest plot of the individual and combined rates of atrial and ventricular lead dislodgements

All studies reported the overall complication rate. The MRI group had a significantly higher rate of pericardial complications (2% vs. 1%, OR 4.23 (95% CI 1.18; 15.10), *p* = 0.03) and a numerically higher overall complication rate in comparison with the control group (6% vs. 3%, OR 2.02 (95% CI 0.88; 4.66), *p* = 0.10) but was not statistically significant, as shown in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} respectively. Tab. [3](#Tab3){ref-type="table"} shows the rates of different individual complications.Fig. 3Forest plot of the individual and combined rates of pericardial complicationsFig. 4Forest plot of the individual and combined rates of overall complicationsTable 3Comparison of outcomesMRI in %Control in %*P*-valueTotal complications6.193.480.100Pericardial complications^a^2.270.680.030Total leads dislodgement3.301.220.008Mean calculated as weighted mean^a^Pericardial complications: pericarditis, pericardial effusion, cardiac tamponade

Sensing parameters of atrial and ventricular leads immediately postoperatively and at follow-up (ranges between 6 weeks and 12 months) were significantly lower in the MRI group. In fact, ventricular lead pacing thresholds were significantly higher in the MRI group at follow up. Tab. [4](#Tab4){ref-type="table"} shows all the lead parameters postoperatively and at follow-up.Table 4Lead parametersAtrial leadsVentricular leadsMRIControl*P*-valueMRIControl*P*-value*Parameters at implant*-- Sensing (mV)  2.71 ± 0.06  3.23 ± 0.060.00035  9.29 ± 1.04 13.41 ± 1.310.062-- Impedance (Ω)562.94 ± 54.24560.17 ± 47.130.171703.34 ± 156.90729.25 ± 105.310.621-- Pacing (V)  0.69 ± 0.16  0.64 ± 0.050.456  0.63 ± 0.11  0.59 ± 0.010.335*Parameters at follow-up* ^a^-- Sensing (mV)  2.84 ± 0.21  3.55 ± 0.150.007  9.94 ± 0.84 15.45 ± 1.500.012-- Impedance (Ω)505.20 ± 14.11514.64 ± 14.000.745539.31 ± 12.49619.74 ± 80.830.237-- Pacing (V)  0.76 ± 0.21  0.71 ± 0.210.935  0.92 ± 0.21  0.72 ± 0.210.038Mean calculated as weighted mean ± standard deviation^a^Follow-up range between 6 weeks and 12 months

Discussion {#Sec11}
==========

Our meta-analysis has demonstrated the following main findings: The rate of pacemaker lead dislodgement (atrial and ventricular) was significantly higher with the use of Medtronic MRI-conditional Revo SureScan Pacing Systems with 5086 leads, with a significantly higher rate of pericardial complications and numerically higher overall complications in comparison with the conventional group.

Many reports have focused on the feasibility and safety of performing MRI scanning on patients with these devices but very few studies have looked at the safety and outcomes of the actual procedures \[[@CR4], [@CR5]\]. Although the studies included in our meta-analysis showed consistently higher complication rates, specifically the rate of pericardial complications with the Medtronic MRI-conditional Revo SureScan Pacing Systems with 5086 leads, two large randomised trials have shown a slightly lower (but likely not significant) rate of pericardial complications. In the EnRhythm MRI Study \[[@CR14]\] and the Advisa MRI Study \[[@CR15]\], there was 1--2% rate of perforation and/or pericardial effusion. Both studies represent specific clinical studies that follow unique, extensive protocols and implanting techniques. This includes pre-implant helix extension and retraction, using slower pin rotations, avoiding driving the lead with a fully seated stylet and avoiding the reverse 'helicoptering' of the 'pinch-on' tool once the helix is extended \[[@CR3], [@CR9]\]. Our meta-analysis represents rather more real-world procedural outcomes that reflect a wide variety of clinical practice.

Although the 5086 lead is a fairly new pacing lead, the outcomes of our study showing a lower safety profile for MRI-conditional PPMs are unlikely to be solely due to the learning curve of implanting physicians with this relatively new technology \[[@CR16]\]. There are many specific design changes incorporated into the leads, including decreasing the number of filars and increasing diameter, increasing the number of turns in the inner coil and increasing the outer lead diameter \[[@CR3]\]. As a result of these changes, the MRI lead is thicker, stiffer and transfers more torque. Sensing parameters of atrial and ventricular leads immediately postoperatively and at follow-up were significantly lower in the MRI group. Also, ventricular lead pacing thresholds were significantly higher in the MRI group at follow-up. While technically (statistically) true, it is unlikely that any of those differences would lead to any meaningful clinical outcome such as under sensing or battery longevity issues.

Three Medtronic leads (5076, 4074 and 4574) have been recently approved for use in the MRI environment and they are smaller in size in comparison with MRI-conditional leads with long-term implanting experience. Hence it is expected that these newly approved MRI-compatible pacing systems will have a wider usage and favourable outcomes, replacing the 5086 pacing leads in the near future. Moreover, other manufacturers have recently introduced MRI-conditional pacing systems; however, more reports are required to assess their safety.

Limitations {#Sec12}
-----------

Some studies were of limited quality given their retrospective nature and single-centre design. The results of our meta-analysis are based on the use of only a specific MRI-compatible lead, and cannot be generalised to all MRI-compatible systems. The discrepancy in follow-up periods among the studies could affect the outcomes. Assessing outcomes such as the complication rate is rather complex and multifactorial. Factors such as different levels of overall and system-specific experience among operators may alter our conclusions. The limited number of articles to be adopted, the small number of events and the short observation period are significant limitations of this meta-analysis. There could have been a lack of statistical power for some outcomes. Analysis related to some of the outcomes showed significant heterogeneity such as overall complications. Nevertheless outcomes such as lead dislodgements had insignificant heterogeneity that could reflect some similarities among studies.

Conclusion {#Sec13}
==========

This meta-analysis supports the safety of conventional PPMs in comparison with the Medtronic MRI-conditional Revo SureScan Pacing Systems with 5086 leads. The rate of pacemaker lead dislodgement was significantly higher in the MRI group. In addition, there were significantly more pericardial complications and a numerically higher overall complication rate in comparison with the conventional group.

Abstract presentation {#Sec14}
---------------------
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